Prenetics Global (PRE) Expected to Announce Earnings on Wednesday

Prenetics Global (NASDAQ:PRE) will likely be announcing its results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $36.15 million for the quarter.

Prenetics Global Stock Up 4.8%

NASDAQ:PRE opened at $21.97 on Friday. The business’s 50-day moving average price is $17.26 and its 200 day moving average price is $13.56. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $22.86. The firm has a market cap of $369.76 million, a P/E ratio of -10.82 and a beta of 0.35.

Analyst Upgrades and Downgrades

PRE has been the topic of several recent research reports. Wall Street Zen raised shares of Prenetics Global from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Roth Mkm started coverage on Prenetics Global in a report on Wednesday. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald raised their price objective on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.00.

Hedge Funds Weigh In On Prenetics Global

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRE. Wells Fargo & Company MN purchased a new stake in shares of Prenetics Global in the fourth quarter valued at $47,000. JPMorgan Chase & Co. acquired a new position in Prenetics Global during the third quarter valued at $65,000. Hudson Bay Capital Management LP purchased a new stake in Prenetics Global in the 4th quarter worth about $296,000. Goldman Sachs Group Inc. purchased a new stake in Prenetics Global in the 4th quarter worth about $665,000. Finally, UBS Group AG boosted its position in Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after acquiring an additional 39,733 shares during the period. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.